In another KRAS-mutant CRC cell line, LoVo, acquired resistance to selumetinib was associated with upregulation of both the mutant and wild type KRAS alleles, but no change in KRAS copy number [Figure 6][11]. This evidence concerns the gene KRAS and colorectal carcinoma.